Premier Alternatives

Freenome

Decision/Risk Analysis · Brisbane, CA · Founded 2014 · Privately Held (backing)

Developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood draw. Freenome is based in Brisbane, CA and was founded in 2014. It is valued at about $2.2 billion as of Oct 2026, set by institutional fund marks. It has raised $1.4 billion across 3 recorded rounds; the latest was a $240 million pipe round in Dec 2025.

PMV mark · valuation
$2.2B
Oct 2026
Priced at
—
Total raised
$1.4B
Last round
PIPE
Dec 2025

Freenome key facts

as of Oct 2026
  • Developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood draw.
  • Freenome is valued at approximately $2.2B as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $1.4B across 3 recorded rounds; the latest was PIPE ($240.0M) in Dec 2025.
  • Notable investors include Andreessen Horowitz, RA Capital Management, GV, Founders Fund, DCVC — 53 tracked in total.
  • 4 institutional filers report fund marks on Freenome across 29 filings.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$2.2B

Reported valuation; nothing comparable since.

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Freenome with a free account
  • ·The complete investor list: 53 names
  • ·Watch Freenome: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Freenome

4 filers · latest Jul 2026

4 SEC-registered funds reported 29 fair-value marks on Freenome between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 29 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Freenome funding rounds

3 rounds
Dec 2025PIPE$240.0M▮
Feb 2024Later Stage VC (Series F)$254.0M▮
Dec 2021Later Stage VC (Series D)$300.0M▮
Full funding history →

Freenome valuation

Freenome is valued at approximately $2.2 billion as of Oct 2026. The figure is set by institutional fund marks.

Recent activity

In the last 90 days, Freenome's record added 3 institutional fund marks (latest period Jul 2026).

How much has Freenome raised?

Freenome has raised $1.4 billion across 3 recorded rounds since 2021. The largest was a $300 million Series D in Dec 2021; the most recent was a $240 million pipe round in Dec 2025.

Institutional holders and vehicles

4 SEC-registered funds reported 29 fair-value marks on Freenome between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Freenome investors

53 investors are on record for Freenome, including Andreessen Horowitz, RA Capital Management, GV and Founders Fund. By type, the record holds 18 venture capital firms, 7 hedge funds and 2 asset managers. The pipe round in Dec 2025 drew 4 investors.

Comparable companies

Comparable decision/risk analysis names by valuation on PrivateMarketView: HeartFlow (NAS: HTFL) ($1.5 billion), Anumana ($580 million) and VideaHealth ($400 million).

About Freenome

Developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood draw. The company's platform uses a proprietary algorithm method that aims to reinvent disease management through systematized early detection and intervention of disease screenings, enabling doctors to treat cancer and other diseases at manageable stages.

Industry
Decision/Risk Analysis
Sector
Healthcare
HQ
Brisbane, CA, United States
Founded
2014
Employees
392
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.